Product How it works Pricing Blog FAQ About Contact
Lineage Cell Therapeutics

Lineage Cell Therapeutics (NYSE: LCTX) revenue

Lineage Cell Therapeutics reported revenue of $14.6m for fiscal 2025, 53.2% more than in fiscal 2024 ($9.5m). Since fiscal 2016 its revenue has grown by 145.8%, an average growth of 10.5% a year.

Lineage Cell Therapeutics has grown its revenue for 2 years in a row, and its best year of the last 10 was fiscal 2022. The biggest drop was in fiscal 2020, −48.1%.

Revenue, in millions of US dollars5.920163.520175.020183.520191.820204.3202114.720228.920239.5202414.62025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$14.6m+53.2%−$36.6m−251.6%
2024$9.5m+6.2%−$21.5m−226.1%
2023$8.9m−39.2%−$24.7m−276.5%
2022$14.7m+238.7%−$22.5m−153.2%
2021$4.3m+137.7%−$49.2m−1,133.6%
2020$1.8m−48.1%−$26.4m−1,448.4%
2019$3.5m−29.5%−$38.9m−1,106.0%
2018$5.0m+44.2%−$41.8m−837.9%
2017$3.5m−41.6%−$38.9m−1,125.0%
2016$5.9m—−$59.0m−995.6%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Lineage Cell Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Lineage Cell Therapeutics ranks 359th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Lineage Cell Therapeutics, 53.2%.

RankCompanyRevenueRevenue growth
357thDianthus Therapeutics$16.1m−7.2%
358thRelay Therapeutics$15.4m53.4%
359thLineage Cell Therapeutics$14.6m53.2%
360thOpus Genetics$14.2m29.1%
361stArbutus Biopharma$14.1m128.2%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Lineage Cell Therapeutics

How much revenue did Lineage Cell Therapeutics make in fiscal 2025?
Lineage Cell Therapeutics reported revenue of $14.6m for fiscal 2025, compared with $9.5m in fiscal 2024.
How much has the revenue of Lineage Cell Therapeutics grown?
Between fiscal 2016 and fiscal 2025 it went from $5.9m to $14.6m: 145.8% more, an average growth of 10.5% a year.
What was the best year for revenue at Lineage Cell Therapeutics?
Of its last 10 fiscal years, fiscal 2022, with $14.7m.
Where does Lineage Cell Therapeutics rank in its sector by revenue?
It ranks 359th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Lineage Cell Therapeutics come from?
From the annual report (Form 10-K) that Lineage Cell Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Lineage Cell Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Lineage Cell Therapeutics: the Lineage Cell Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.